Noticias de CELC_US
Noticias del mercado
Últimas noticias sobre CELC_US — 208 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Celcuity (CELC) Sees Significant Drop Amid Market Fluctuations
Celcuity (CELC) Faces Significant Decline of 22.2%
Celcuity Inc., con sede en Minneapolis, fue como los Rolling Stones en la reunión anual de 2026 de la Sociedad Estadounidense de Oncología Clínica. La compañía informó datos positivos de fase III para su inhibidor pan-PI3K/mTORC1/2 gedatolisib, pero Celcuity (NASDAQ:CELC) no pudo obtener ninguna satisfacción de los inversores, que hicieron que las acciones cayeran un 25,7%, o 31,54 dólares, hasta 91,42 dólares el 2 de junio de 2026.
Stifel reiterates Celcuity stock rating on trial data By Investing.com
Stifel reiterates Celcuity stock rating on trial data By Investing.com
Leerink cuts Celcuity stock price target on trial results By Investing.com
According to a document submitted to the US Securities and Exchange Commission (SEC), the Gedatolisib treatment regimen evaluated by Celcuity Inc in its clinical studies has demonstrated favorable tolerability characteristics.
Stifel reiterates Celcuity stock rating on trial data By Investing.com
According to a document filed with the U.S. Securities and Exchange Commission, data released by Celcuity Inc shows that its Gedatolisib triplet therapy achieved significant results in a pivotal trial.
According to a document filed with the U.S. Securities and Exchange Commission, data released by Celcuity Inc shows that its Gedatolisib triplet therapy achieved significant results in a pivotal trial.
Celcuity’s gedatolisib shows superior results in breast cancer trial By Investing.com
Celcuity’s gedatolisib shows superior results in breast cancer trial By Investing.com
Celcuity’s gedatolisib shows superior results in breast cancer trial By Investing.com
Celcuity’s gedatolisib shows superior results in breast cancer trial By Investing.com
Celcuity stock tumbles 15% despite positive trial results
Las acciones de Celcuity Inc. (NASDAQ:CELC) cayeron un 15 % el martes incluso después de que la compañía publicara resultados positivos detallados de eficacia y seguridad de la cohorte de mutantes PIK3CA de su estudio de fase 3 VIKTORIA-1 que evalúa gedatolisib en pacientes con cáncer de mama avanzado o metastásico con receptor hormonal positivo, HER2 negativo y mutación PIK3CA.
Página 6 de 11
